Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development
TheFly reported on June 15 that Oppenheimer initiated coverage of AAPG with an Outperform rating and a $45 price target.
Ascentage Pharma Group International (AAPG)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 16,056 | $383,257 | -5% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,014 | $310,644 | 0.31% | |
| 2. | 518 | $12,365 | 0% | |
| 3. | 498 | $11,887 | 0% | |
| 4. | 124 | $2,960 | 0% | |
| 5. | 24 | $573 | 0% |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
10 Stocks That Have the Potential to Rise 1000%
Stocks with high upside are rarely obvious at the start. The market usually sees a small company, an unproven business model, or a story that still needs execution.
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target
On January 14, Rodman & Renshaw initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $48 price target, citing the company’s differentiated hematology-focused...
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement
Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best performing mid cap stocks so far in 2025.
11 Best Performing Mid Cap Stocks So Far In 2025
On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility.
Ascentage Pharma's Novel Cancer Drug Approved in China
Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years.
12 Best Young Stocks To Buy and Hold For 5 Years
On July 2, Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' to discuss the market's momentum in the second half of 2025.
11 Best Performing Healthcare Stocks to Buy Now
On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector.
Hedge Fund Resource Center